Date Title Description PDF
21 Feb 2023 On business and financial situation The Company releases the press release related to the full year 2022 financial results. Download
21 Feb 2023 On business and financial situation The company releases the Integrated Report for the year 2022 Download
21 Feb 2023 About Corporate Governance The Company informs about the agreements adopted by the Board of Directors Download
23 Nov 2022 On business and financial situation The Company releases the presentation related to its strategy update because of its 2022 Capital Markets Day   Download
04 Nov 2022 On business and financial situation The Company releases the press release related to the first nine months of 2022 financial results Download

Pages

Date Title Description PDF
27 Jul 2022 On business and financial situation The Company releases the first half 2022 financial results presentation Download
04 Jul 2022 Liquidity and counterparty agreements Liquidity contract: transactions conducted in the second quarter of 2022 Download
30 Jun 2022 Other relevant information The Company informs about the dividends payment Download
16 Jun 2022 Other relevant information The Company has agreed to execute the capital reduction approved by the 2022 Ordinary General Meeting to amortize the shares acquired in the framework of the own shares repurchase programs   Download
14 Jun 2022 Announcement of general shareholders’ meeting ROVI releases the information related to its General Shareholders Meeting Download

Pages

Date Title Description PDF
08 Jan 2018 Contratos de liquidez y contrapartida Liquidity contract: transactions conducted in the fourth quarter of 2017 Download
21 Dec 2017 Préstamos, créditos y avales ROVI and the EIB agree to sign a loan to boost research into drug administration and prolonged-release technologies Download
08 Nov 2017 Información sobre Resultados ROVI releases the press release related to the nine-month period ended 30 September 2017 results Download
08 Nov 2017 Información sobre Resultados ROVI releases the presentation related to the nine-month period ended 30 September 2017 results. Download
24 Oct 2017 Otros sobre negocio y situación financiera The Company releases the presentation related to the update of its Phase III-Prima 3 Risperidone ISM® project. Download

Pages